Rahul Bhargava: Landmark Study Shows Excellent Outcomes in Pediatric AML Transplant
Rahul Bhargava, Director and Head of Hematology, Hematoncology and Stem Cell Transplant at Fortis Health Care, posted on LinkedIn:
”Dr Vikas Dua makes Fortis Healthcare and India proud with its exceptional outcomes of Bone Marrow transplant in Pediatric AML
2nd biggest paper after sickle cell one
Proud Moment for FMRI Pediatric Hematology and BMT Team!
Our landmark study, “Excellent Outcomes of Hematopoietic Stem Cell Transplant for Pediatric High-Risk and Relapsed Acute Myeloid Leukemia,” has been published in the Journal of Pediatric Hematology/Oncology (JPHO)!
Study Highlights:
- Median age at transplant: 8.5 years
- Male : Female ratio: 1.9 : 1
- Total patients: 48 (46 de novo AML + 2 secondary AML)
- Donor types: 29 MSD | 3 MRD | 18 Haploidentical HSCT
- Conditioning regimen: Fludarabine-based (all engrafted)
- Cumulative relapse: 16 %
- Median follow-up: 40.9 months
- Event-Free Survival (EFS): 78 %
- Overall Survival (OS): 86 %
- Non-Relapse Mortality (NRM): 6 %
- Matched vs Haplo HSCT: EFS 78.1 % vs 77.8 % (p = 0.78); OS 84.4 % vs 88.9 % (p = 0.83)
These outcomes reaffirm that Haploidentical HSCT can achieve results comparable to matched donor transplants, expanding access to curative therapy for children with high-risk AML.
Heartfelt gratitude to Dr Vikas Dua dedicated physician-scientist making Fortis and India proud, and to the incredible team — Swati Bhayana, Arun Danewa Sohini, Dr Parminder, our nurse practitioners, Aastha Gupta, Dr. Neha Rastogi Panda, Shrinidhi Nathany, Amit Pal Singh Raina, Geetanjali Gupta for their remarkable work and perseverance.
Special congratulations to Sunisha Arora , our Associate Consultant, for leading this effort and getting it in black and white! Yashpal Singh Rawat, Dr Ritu Mittal Garg, Dr. Abhishek Sharma, Anusha S., Rachit Agrawal, Nikhil M Kumar.
You truly deserve a grand celebration!”
Stay updated with Hemostasis Today.
-
Nov 3, 2025, 08:23The 1st Participant in A New CHECK-NIRS Clinical Study is Enrolled!
-
Nov 3, 2025, 08:15Bert van Meurs Shares the New Late-breaking Results from the iMODERN Trial
-
Nov 3, 2025, 07:10Lisa Shea Shares Key Takeaways from NORD Summit 2025
-
Nov 3, 2025, 06:49Darshan Doshi on Results of iMODERN and ILIAS ANOCA Studies Presented at TCT 2025
-
Nov 2, 2025, 14:172019 ESC/EAS Guidelines for the Management of Dyslipidaemias Discussion with Lale Tokgözoğlu and Jeanine Roeters van Lennep
-
Nov 3, 2025, 09:13Claudio Carrubba on How Timing Truly Matters in Trauma Embolization
-
Nov 3, 2025, 08:46Rachel Lamerton and Colleagues on Activation of Platelets in Flow Cytometry
-
Nov 3, 2025, 04:56Nirupama Ramadas and Erica Sparkenbaugh on Thromboinflammation in SCD
-
Nov 2, 2025, 14:21Claude Franceschi: I Advise You to Understand the Hemodynamic Pathophysiology of Venous Diseases Rather than Blindly Applying Ablation Techniques or Venous Stent Placement
-
Nov 2, 2025, 14:15Krishna Aragam: Why are (DCM) and Heart Failure About Twice as Common in Individuals of Self-Identified Black Race?
-
Oct 29, 2025, 07:31The Use of Artificial Intelligence to Improve Detection of Acute Incidental Pulmonary Emboli - JTH
-
Oct 29, 2025, 07:05Shrinidhi Nathany: AI in Diagnostic Medicine
-
Oct 28, 2025, 07:02Aya Berman: AI Model for Predicting Bacteremia
-
Oct 28, 2025, 06:55The New Era of Genomics, AI and Cell Therapy in Hematology and Infectious Diseases
-
Oct 28, 2025, 06:49Lukas Gaats: Researchers Are Building Reproductive Organoids
-
Nov 3, 2025, 09:24Stephen Cornelissen: It’s Not Just About Emergencies — It’s About Everyday Care, Chronic Conditions and Hope
-
Nov 3, 2025, 06:57Maria Elisa Mancuso Reflects on 2025 Annual Congress of the Italian Association of Hemophilia Centres
-
Nov 3, 2025, 05:46Chandra Viswanathan: When Blood Safety Fails, We All Bleed - A Call for Reform and Responsibility
-
Nov 2, 2025, 14:17Anamaria B: Your Mother Still Runs Part of Your DNA
-
Nov 2, 2025, 10:57Paul Bolaji on Launching The First Centralised Nigerian National Stroke Registry